Clinical Policy: Avutometinib; Defactinib (Avmapki Fakzynja Co-Pack)
Customize your policy alerts
Sign up for mhn Policy CP.PHAR.731 alerts
Get alerted when Policy CP.PHAR.731 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity criteria, initial and continued authorization requirements, dosing limits, contraindications, therapeutic alternatives, and prior authorization expectations for Avmapki Fakzynja Co-Pack across Commercial, HIM, and Medicaid lines of business.
Policy created May 15, 2025 with P&T approval date 08.25.25.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.